ConvaTec receives US approval for novel wound care system

International medical products and technologies company ConvaTec Group announced today that is received clearance from the US Food and Drug Administration for its Avelle Negative Pressure Wound Therapy (NPWT) system.

The Deeside-based company said the novel system is its entry into the fast-growing disposable space of the £860m NPWT market.

ConvaTec’s Avelle product is used to create a negative pressure moist wound environment to aid healing of a variety of different wounds, including chronic, acute, traumatic, and sub-acute wounds, skin grafts, and surgically closed incisions.

It includes a small, portable, pocket-sized pump which can be used for up to 30 days.

ConvaTec says the Avelle system is the only product on the market to offer this combination of advanced wound care technologies.

Fiona Adam, ConvaTec interim president, advanced wound care, said: “We are very pleased to bring the benefits of the Avelle NPWT system to healthcare professionals and patients in the US, where demand for disposable single-use negative pressure devices is growing at double digit rates.

“Customer response in European markets has been very positive, with clinicians and patients noting the disposable system’s ease of use, as well as its suitability from hospital to home.

“At ConvaTec, we are committed to providing our customers with further differentiated technologies and complete solutions for managing chronic and acute wounds, and helping them improve outcomes with the right product, for the right patient, at the right time,” she added.

The Avelle NPWT system is currently available in 24 markets, including the UK, Germany, France, Canada, Australia and South Africa.